BiotechTube
Home/Enanta Pharmaceuticals/Jay R. Luly, Ph.D.
JR

Jay R. Luly, Ph.D.

President, Chief Executive Officer and Director

Enanta Pharmaceuticals

Therapeutic Areas

VirologyImmunology

Enanta Pharmaceuticals Pipeline

DrugIndicationPhase
Zelicapavir (EDP-938)Respiratory Syncytial Virus (RSV) InfectionPhase 2b
EDP-323SARS-CoV-2 InfectionPhase 1
EDP-978Type 2 Inflammatory Diseases (e.g., CSU)Preclinical
STAT6 Inhibitor ProgramType 2 Inflammatory DiseasesPreclinical
MRGPRX2 ProgramInflammatory Diseases (e.g., CSU)Discovery/Preclinical